The global methicillin-resistant staphylococcus aureus (MRSA) treatment market is experiencing substantial growth, driven by an urgent need for effective solutions against these resilient infections. According to a recent report by Future Market Insights (FMI), the market surged to USD 3.9 billion in 2022 and is projected to reach USD 5.5 billion by 2030, with a robust Compound Annual Growth Rate (CAGR) of 4.3%.
This upward trajectory underscores the escalating global demand for cutting-edge treatments to combat MRSA infections. Future Market Insights, a leader in market research and consultancy services, is uniquely positioned to capitalize on this lucrative opportunity. With a steadfast commitment to pioneering research and development, FMI continues to lead the charge against MRSA, offering innovative solutions to address the evolving challenges posed by this drug-resistant pathogen.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-10406
However, the MRSA treatment market is not without its obstacles. Limited access to effective treatments and misdiagnoses of MRSA infections are significant barriers to market expansion. Additionally, the high costs associated with MRSA treatment, especially in emerging economies, are expected to hinder adoption rates.
Inaccurate diagnoses can lead to inappropriate treatment plans, resulting in severe complications and even fatalities. These factors present substantial challenges to market growth in the near future.
Future Market Insights recognizes the critical need to overcome these challenges to ensure that effective MRSA treatment reaches those who need it most. Through its commitment to in-depth research and industry insights, FMI empowers healthcare providers and policymakers with the knowledge required to make informed decisions regarding MRSA treatment strategies and resource allocation.
By collaborating with stakeholders across the healthcare spectrum, Future Market Insights is dedicated to advancing MRSA treatment and diagnostics. This collaborative approach not only drives innovation but also ensures that the most effective treatments are accessible to all, ultimately contributing to a healthier future for everyone.
Key Takeaways of Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry Study:
- In terms of drug class, glycopeptides (vancomycin) and oxazolidinones (linezolid) are collectively expected to account for over 75% of revenue share in the MRSA treatment market owing to preference of both antibiotic classes as a first-line treatment against MRSA infections and used in more than 80% of MRSA cases treatment.
- By route of administration, intravenous (IV) route of administration remains the recommended option. Drugs that can be administered through IV are likely to gain more than one-half of market share in the MRSA treatment market during the forecast period.
- By indication, skin and soft tissue infections (SSTIs) are leading the market and expected to gain more than 40% of revenue share followed by the pneumonia over the forecast period.
- Incidence of healthcare acquired MRSA is higher than community acquired MRSA, and FMI opines status-quo to remain unchanged during the assessment period
- North America is the highest revenue generating market by region due to high incidence of MRSA infections
- Asia Pacific is expected to witness high demand for MRSA testing systems due to high incidences of MRSA infection herein. For example – Journal of Family Medicine and Primary Care, in 2021, stated that occurrence of MRSA among kids aged 5 to 15 is between 16 and 52%. India alone accounts for 4-19% of these infections.
Get Customization on This Report: https://www.futuremarketinsights.com/customization-available/rep-gb-10406
Government and Pharma Industry Focus on Working in Unison to Develop Advanced Treat:
As per University of Melbourne’s researchers, “Teixobactin” responds positively against MRSA. These results are likely to pave the way for development of antibacterial drugs to treat multi-drug resistant Gram-positive infections with thick cell wall. This will open wider doors for MRSA treatment market all over Australia and the other countries in Asia-Pacific. Teixobactin is already known for destroying Mycobacterium tuberculosis.
Key Companies Profiled:
- Pfizer, Inc.
- Allergan Plc.
- Johnsons & Johnson
- Colgate-Palmolive Company
- The Procter & Gamble
- Merck & Co., Inc.
- Baxter Healthcare Corporation
- Fresenius Kabi LLC
- Sandoz Inc.
- Teva Pharmaceutical Industries ltd.
- Mylan N. V.
- Dr.Reddy’s Laboratories Inc.,
- Cumberland Pharmaceuticals Inc.
Methicillin-Resistant Staphylococcus Aureus (MRSA) Treatment Industry By Category:
By Drug Class:
- Glycopeptides
- Vancomycin
- Oxazolidinones
- Linezolid
- Lipopeptides
- Daptomycin
- Antiseptics
- Chlorhexidine
- Cetylpyridinium Chloride
- Hydrogen Peroxide
- Phenols
- Lipoglycopeptides
- Dalbavancin
- Telavancin
- Oritavancin
- Glycylcycline
- Tigecycline
- Streptogramins
- Quinupristin
- Dalfopristin
- Naturals/Herbals
- Tetracycline
- Doxycycline
- Minocycline
- Lincomycin
- Clindamycin
- Others
By Indication:
- Skin and Soft Tissue Infections (SSTIs)
- Pneumonia
- Bloodstream Infections
- Surgical and Medical Infections
- Others
By Route of Administration:
- Intravenous
- Oral
- Topical
- Nasal
- Cutaneous
- Intramuscular
By Type of MSRA:
- Healthcare Acquired MRSA
- Community Acquired MRSA
- Hospital Acquired MRSA
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online Pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
A Comprehensive Full Report: https://www.futuremarketinsights.com/checkout/10406
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
